Review

Use of del Nido cardioplegia in adult cardiac surgery

Volume: 8 Number: 1 January 4, 2022
EN

Use of del Nido cardioplegia in adult cardiac surgery

Abstract

In most adult cardiac surgery operations, the heart must be completely immobile and isolated from the blood. Therefore, the heart is stopped in diastole and a still operative site is obtained. Cardiac arrest results in ischemia-reperfusion injury. For these reasons, myocardial protection and the prevention of damages are required. Various cardioplegia solutions are used for this purpose. It can be said that cardioplegia is the gold standard method of myocardial protection in cardiac arrest. Nowadays, "Single-dose cardioplegia" applications are increasingly used, especially in minimally invasive cardiac surgery and basic coronary bypass procedures due to the advantages they provide, which include reduction of aortic cross-clamp time, prevention of frequent interruption of the procedure due to cardioplegia, and reduced postoperative myocardial dysfunction incidence. The two main solutions used in single dose cardioplegia applications are the Bretschneider solution and the del Nido extracellular cardioplegia solution. The del Nido cardioplegia solution (dNCS), which was originally developed for use in pediatric cardiac surgery, has recently increased its use in adult cardiac surgery due to straightforward application and long-term effectiveness. The del Nido cardioplegia reduces the aortic cross clamp duration, cardiopulmonary bypass time and required cardioplegia solution volume, and is a safer and superior cardioplegia solution and technique in terms of myocardial protection with regards to many organs and cardiac-biochemical parameters.

Keywords

References

  1. 1. Chambers DJ. Mechanisms and alternative methods of achieving cardiac arrest. Ann Thorac Surg 2003;75:S661-6.
  2. 2. Yamamoto H, Yamamoto F. Myocardial protection in cardiac surgery: a historical review from the beginning to the current topics. Gen Thorac Cardiovasc Surg 2013;61:485-96.
  3. 3. Ferguson ZG, Yarborough DE, Jarvis BL, Sistino JJ. Evidence-based medicine and myocardial protection–where is the evidence? Perfusion 2017;21:30-5.
  4. 4. Braathen B, Jeppsson A, Scherste´n H, Hagen OM, Vengen Ø, Rexius H, et al. One single dose of histidine-tryptophan-ketoglutarate solution gives equally good myocardial protection in elective mitral valve surgery as repetitive cold blood cardioplegia: a prospective randomized study. J Thorac Cardiovasc Surg 2011;141:995-1001.
  5. 5. Dobson GP, Jones MW. Adenosine and lidocaine: a new concept in nondepolarizing surgical myocardial arrest, protection, and preservation. J Thorac Cardiovasc Surg 2004;127:794-805.
  6. 6. Gorgy A, Shore-Lesserson L. Del Nido cardioplegia should be used in all adults undergoing cardiac surgery: Con. J Cardiothorac Vasc Anesth 2019; 33:1791-4.
  7. 7. Talwar S, Bhoje A, Sreenivas V, Makhija N, Aarav S, Choudhary SK, et al. Comparison of del Nido and St Thomas cardioplegia solutions in pediatric patients: a prospective randomized clinical trial. Semin Thorac Cardiovasc Surg 2017;29:366‐74.
  8. 8. Ramani J, Malhotra A, Wadhwa V, Garg P, Tarsaria M, Pandya H. Single-dose lignocaine based blood cardioplegia in single valve replacement patients. Braz J Cardiovasc Surg 2017;32:90-5.

Details

Primary Language

English

Subjects

Cardiovascular Surgery

Journal Section

Review

Publication Date

January 4, 2022

Submission Date

July 12, 2021

Acceptance Date

November 1, 2021

Published in Issue

Year 2022 Volume: 8 Number: 1

AMA
1.Amaç B, Selçuk M, Bölükbaş S, et al. Use of del Nido cardioplegia in adult cardiac surgery. Eur Res J. 2022;8(1):139-144. doi:10.18621/eurj.970465

Cited By